Dramatic advances in the fields of biochemistry, cell and molecular biology, genetics, biomedical engineering and materials science have given rise to the remarkable new cross-disciplinary field of tissue engineering. Tissue engineering uses synthetic or naturally derived, engineered biomaterials to replace damaged or defective tissues, such as bone, skin, and even organs.
Research by engineers and cancer biologists at Virginia Tech indicate that using specific silicon microdevices might provide a new way to screen breast cancer cells' ability to metastasize.
Research by engineers and cancer biologists at Virginia Tech indicate that using specific silicon microdevices might provide a new way to screen breast cancer cells' ability to metastasize.
New technologies and methods are spurring a renaissance in the study of organogenesis. Organogenesis, essentially the process through which a group of cells becomes a functioning organ, has important connections to biological processes at the cellular and developmental levels, and its study offers great potential for medical treatments through tissue engineering approaches.
Researchers from Cornell University and Weill Cornell Medical College have been awarded $100,000 by NFL Charities, the charitable foundation of the National Football League owners, to research tissue engineering for spinal injuries.
Nutritional supplementation with Spirulina, a nutrient-rich, blue-green algae, appeared to provide neuroprotective support for dying motor neurons in a mouse model of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, University of South Florida neuroscientists have found.
Organovo, Inc., a regenerative medicine company focused on bioprinting technology, today announced the release of data on the first fully bioprinted blood vessels. Data was presented at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) meeting in Orlando, Florida. The blood vessels were created through the use of the NovoGen MMX Bioprinter, Organovo's proprietary platform for the creation of 3D tissue constructs.
Arteriocyte, Inc., a leading clinical stage biotechnology company with offices in Cleveland, Ohio, and Hopkinton, Massachusetts, that develops proprietary stem cell and tissue engineering based therapies announced today the launch of its first commercially available Stem Cell Expansion System for research use.
Breast cancers that arise sporadically, rather than through inheritance of certain genes, likely start with defects of DNA repair mechanisms that allow environmentally triggered mutations to accumulate, according to researchers at the University of Pittsburgh School of Medicine, Magee-Womens Hospital of UPMC and the University of Pittsburgh Cancer Institute.
Coatings functionalize surfaces or protect them from processes such as corrosion, abrasion, and weathering, and may provide an aesthetic appearance—automotive coatings and non-stick frying pans are good examples. Contact lenses, implants, LEDs, or photovoltaic cells require extremely thin coatings. In the journal Angewandte Chemie, the teams led by Gero Decher at the Institut Charles Sadron in Strasbourg (France) have now introduced a new process for the production of ultrathin coatings that is especially simple, versatile, and suitable for large-scale processes.
Researchers in the United States have developed a medical model for regenerating bladders using stem cells harvested from a patient's own bone marrow. The research, published in STEM CELLS, is especially relevant for paediatric patients suffering from abnormally developed bladders, but also represents another step towards new organ replacement therapies.
Researchers have started the world’s first clinical trial of stem cells to treat stroke victims in Glasgow. The trial is undertaken by ReNeuron, a Guildford-based biotech company and started this weekend with an elderly man receiving an injection of 2 million stem cells into his brain. It received final approval to go ahead this year.
It is well known that oral infection progressively destroys periodontal tissues and is the leading cause of tooth loss in adults. A major goal of periodontal treatment is regeneration of the tissues lost to periodontitis. Unfortunately, most current therapies cannot predictably promote repair of tooth-supporting defects. A variety of regenerative approaches have been used clinically using bone grafts and guiding tissue membranes with limited success.
CMU's Jeffrey O. Hollinger, director of the center, and Professor Krzysztof Matyjaszewski have received a three-year, $2.9 million U.S. Department of Defense research grant to develop a therapy that would aid amputees, specifically wounded soldiers. The therapy aims to prevent bone nodules from forming in the muscle at the site of amputation, a painful condition that makes it difficult for amputees to wear limb prostheses.
With a failure rate as high as 50 percent, bone tissue grafts pose a significant obstacle to orthopedic surgeons attempting to repair complex fractures or large areas of bone loss, such as those often caused by trauma and cancer. Current synthetic substitutes rarely possess the bone-like properties needed for successful grafting and are often difficult for surgeons to manipulate in the operating room. In response to these challenges, researchers at UMass Medical School have developed an easy-to-produce, inexpensive, synthetic bone material called FlexBone.
Shrink Nanotechnologies, Inc. an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that it has entered into an agreement to produce a high content screening tool for its biotech R&D subsidiary, Shrink Chips LLC.
Shrink Nanotechnologies, Inc. an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, revealed an image of its first product offering the StemDisc450, a high-yield, low cost, patent-pending cell culturing biomedical research tool.
Balaji Sitharaman, Ph.D., Assistant Professor of Biomedical Engineering at Stony Brook University, is a 2010 recipient of the National Institutes of Health (NIH) Director's New Innovator Award.
Danny Bluestein, Ph.D., Professor of Biomedical Engineering at Stony Brook University, has been awarded a five-year, $7.5 million grant by the National Institutes of Health. The award marks the first time a Stony Brook professor has received a Phase II Quantum Grant, given by The National Institute of Biomedical Imaging and Bioengineering (NIBIB), a division of the NIH, to make a profound improvement or quantum leap forward—in health care.
In an expansion of its ongoing effort to promote the next generation of stem cell scientists, The New York Stem Cell Foundation (NYSCF) today named the first six NYSCF Investigators. Each of the NYSCF-Robertson and NYSCF-Helmsley Investigators will receive up to $1.5 million over the next five years to expand their own laboratories, train other scientists and foster innovative high-risk/high reward research to explore the therapeutic potential of stem cells derived from humans and model organisms.
NovaSterilis, Lansing NY, and Dr. CC Chu were awarded a grant from the Metropolitan Development Association (MDA) to explore the feasibility of utilizing NovaSterilis supercritical co2 sterilization for a variety of absorbable biomaterials from both commercial and experimental sources.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.